Form 4: Neuronetics Director Sheryl Conley Awarded 30,000 Restricted Stock Units

Neuronetics, Inc. Director Sheryl L. Conley has been granted 30,000 restricted stock units (RSUs) as part of her compensation, aligning her interests with long-term shareholder value.

Summary

• Sheryl L. Conley, a Director of Neuronetics, Inc. (STIM), acquired 30,000 shares of Common Stock through a Restricted Stock Unit (RSU) award.
• The transaction date for this acquisition was May 22, 2025.
• Following this transaction, Ms. Conley beneficially owns 214,390 shares of Common Stock directly.
• Each RSU represents a contingent right to receive one share of Neuronetics' common stock.
• The RSU award vests on the earlier of May 22, 2026, or Ms. Conley's Board-approved separation of service from the Issuer, contingent upon her continuous service through the vesting date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU award aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. However, it's a routine transaction with no significant immediate impact on company operations or financials.

Positives

• The RSU award aligns the director's interests with long-term shareholder value, as the value of the award is tied to the company's stock performance.
• Granting RSUs is a common practice for compensating directors, promoting retention and commitment to the company's success.

Negatives

• The issuance of 30,000 RSUs, upon vesting, will result in a minor dilution of existing shareholder equity, though this is typical for equity compensation plans.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries for publicly traded companies. It reflects standard compensation practices for board members in the medical device or healthcare technology sector, where equity awards are frequently used to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The RSU award to Sheryl L. Conley, a Director of Neuronetics, Inc., constitutes a related party transaction as it involves an equity grant from the company to an insider.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting of the RSUs, but generally positive for aligning director incentives with shareholder interests.
• Director (Sheryl L. Conley): Receives equity compensation, tying her personal financial interest directly to the company's stock performance.

Next Steps

• The 30,000 RSUs are expected to vest on May 22, 2026, or earlier upon Board-approved separation of service, subject to continuous service.

Key Dates

Keywords

Neuronetics, STIM, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, SEC Form 4, Equity Award, Corporate Governance